In a report released yesterday, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Taysha Gene Therapies (TSHA – Research Report), with a price target of $7.00.
Whitney Ijem has given his Buy rating due to a combination of factors surrounding the progress and potential of Taysha Gene Therapies. The company’s lead program, TSHA-102, targeting Rett Syndrome, has demonstrated promising initial safety and efficacy results in adult patients. These positive outcomes, combined with the program’s expansion to include younger patients, suggest a strong trajectory that could continue to build momentum with further updates expected in the near future. The large addressable market for Rett Syndrome in the US, EU, and UK, paired with the current lack of adequate treatments, underscores the significant opportunity for Taysha’s therapy.
Furthermore, TSHA-102’s innovative design, incorporating a miniMECP2 gene, a neuronal specific promoter, and a self-regulating feedback mechanism, positions it favorably in the gene therapy space. The therapy has already received rare pediatric disease and orphan drug designations from the FDA, enhancing its regulatory prospects. The miRARE platform’s capacity to regulate gene expression and prevent potential toxicity provides a compelling argument for the therapy’s safety profile. These scientific and regulatory advantages, coupled with the upcoming pediatric data expected by mid-year, fortify Ijem’s confidence in Taysha Gene Therapies and justify the Buy rating.
See today’s best-performing stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Taysha Gene Therapies (TSHA) Company Description:
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.
Read More on TSHA:
- Taysha Gene Therapies provides update on deprioritized pipeline programs
- Taysha Gene Therapies Provides Update on Deprioritized Pipeline Programs
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Taysha Gene Therapies announces inducement grant under Nasdaq listing rule
- Taysha Gene Therapies Announces Poster Presentation on TSHA-102 in Rett Syndrome at Upcoming British Paediatric Neurology Association 2024 Annual Conference
